

04-25-02

1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PH#8

In re application of: Ulrich MARTIN et al.

Application No. 09/917,410

Filed: July 26, 2001



Art Unit: 1644

Examiner: Not Yet Assigned

Attorney Docket: 05882.0002.CNUS01

For: **ANTI-SELECTIN ANTIBODIES FOR PREVENTION OF MULTIPLE ORGAN FAILURE AFTER POLYTRAUMA AND FOR PREVENTION OF ACUTE ORGAN DAMAGE AFTER EXTRACORPOREAL BLOOD CIRCULATION**

RECEIVED

APR 29 2002

Information Disclosure Statement

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required, or
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
 - ☐ c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of

Allowance, but on or before payment of the Issue Fee. Attached is our Check No.

_____ in the amount of \$ _____ in payment of the fee under 37 C.F.R.

§ 1.17(i), and

- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from any foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under


35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R.
§ 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 05882.0002.CNUS01.

Respectfully submitted,

Date: April 23, 2002


Albert P. Halluin (Reg. No. 25,227)
Robin C. Chiang (Reg. No. 46,619)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box 34
Menlo Park, CA 94025
(650) 463-8109

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET

05882.0002:US01

APPLICATION NO.

09/917,410

APPLICANT

Ulrich MARTIN, et al.

FILING DATE

July 26, 2001

RECEIVED
APR 23 2002
TECH CENTER 1600/2900



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1.	5,316,913	5/31/94	Butcher, <i>et al.</i>	435	7.24	9/6/91
	A2.	5,460,945	10/24/95	Springer, <i>et al.</i>	435	7.24	5/20/92
	A3.	5,622,701	4/22/97	Berg	424	153.1	6/14/94
	A4.	5,679,346	10/21/97	Tedder, <i>et al.</i>	424	141.1	6/7/95
	A5.	5,756,095	5/26/98	Jutila	424	144.1	5/26/98

FOREIGN PATENT DOCUMENTS


*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	B1.	WO 93/00111	1/17/93	PCT	5		
	B2.	WO 93/02698	2/18/93	PCT	5		
	B3.	WO 94/12215	6/9/94	PCT	5		
	B4.	WO 95/15181 A1	6/8/95	PCT	6		

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

C1.	Buerke, et al., "Humanized Monoclonal Antibody DREG-200 Directed Against L-Selectin Protects in Feline Myocardial Reperfusion Injury", <i>J. Pharm. Exp. Ther.</i> <u>271</u> :134-142 (1994).
C2.	Elliot, et al., "Interaction Between Neutrophils and Endothelium", <i>Ann Thorac. Surg.</i> <u>56</u> :1503-1508 (1993).
C3.	Finn, et al., Systemic Inflammation During Paediatric Cardiopulmonary Bypass: Changes in Neutrophil Adhesive Properties", <i>Perfusion</i> <u>8</u> :39-48 (1993).
C4.	Kishimoto, et al., "Identification of a Human Peripheral Lymph Node Homing Receptor: A Rapidly Down-regulated Adhesion Molecule", <i>Proc. Natl. Acad. Sci. USA</i> , <u>87</u> :2244-2248 (1990).
C5.	Kuratani, "Experimental Study on the Mechanism of Lung Injury following Cardiopulmonary Bypass (Using Unilateral Pulmonary Artery Occlusion Model in Rabbit)" <i>Osaka University Med. J.</i> <u>42</u> :69-85 (1990).
C6.	Lin, et al., "Selectin Neutralization: Does it Make Biological Sense?", <i>Crit. Care Med.</i> <u>27</u> :2050-2053 (1999).
C7.	Mileski, et al., "Inhibition of CD18-dependent Neutrophil Adherence Reduces Organ Injury After Hemorrhagic Shock in Primates", <i>Surgery</i> , <u>108</u> :206-212 (1990).
C8.	Moat, et al., Humoral and Cellular Activation in a Simulated Extracorporeal Circuit", <i>Ann Thorac Surg.</i> <u>56</u> :1509-14 (1993).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449 	ATTY. DOCKET 05882.0002.CNUS01	APPLICATION NO. 09/917,410
	APPLICANT Ulrich MARTIN, <i>et al.</i>	
	FILING DATE July 26, 2001	GROUP 1644

C9.	Schlag, <i>et al.</i> , "Anti-L-selectin Antibody Treatment of Hemorrhagic-traumatic Shock in Baboons", <i>Crit. Care Med.</i> , <u>27</u> :1900-1907 (1999).
C10.	Winn, <i>et al.</i> , "Monoclonal Antibodies to Leukocyte and Endothelial Adhesion Molecules Attenuate Ischemia-Reperfusion Injury", <i>Behring Inst. Mitt.</i> , <u>92</u> :229-237 (1993).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.